BRÈVE

sur SANOFI-AVENTIS (EPA:SAN)

Sanofi and Novavax Form Strategic Alliance to Enhance Vaccine Accessibility

Sanofi and Novavax announced a new licensing agreement to co-commercialize a COVID-19 vaccine and develop combination vaccines against flu and COVID-19. This partnership aims to expand availability of a protein-based non-mRNA COVID-19 vaccine from 2025. Jean-Francois Toussaint, the Global Head of Vaccines R&D at Sanofi, emphasized the synergy between Novavax's adjuvanted vaccine and Sanofi’s flu vaccines, which could improve convenience and protection against respiratory viruses.

John Jacobs, CEO of Novavax, highlighted the importance of this collaboration for public health. The partnership will leverage Novavax's technologies and Sanofi's expertise in vaccine commercialization to widen access to effective vaccines. Financially, the terms of the agreement involve an upfront payment from Sanofi to Novavax of $500 million with potential earnings totaling up to $1.2 billion.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SANOFI-AVENTIS